Should I buy or sell MeiraGTx stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGTX shares. View MGTX analyst ratings or view top-rated stocks .

What is MeiraGTx's stock price target for 2024?

2 analysts have issued 12 month price targets for MeiraGTx's shares. Their MGTX share price targets range from $11.00 to $41.00. On average, they expect the company's share price to reach $25.67 in the next year. This suggests a possible upside of 265.6% from the stock's current price. View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts .

How have MGTX shares performed in 2023?

MeiraGTx's stock was trading at $6.52 at the beginning of the year. Since then, MGTX stock has increased by 7.7% and is now trading at $7.02. View the best growth stocks for 2023 here .

When is MeiraGTx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our MGTX earnings forecast .

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.11. The company had revenue of $5.10 million for the quarter, compared to the consensus estimate of $3.54 million.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Inovio Pharmaceuticals (INO) , Kadmon (KDMN) , Pfizer (PFE) , VBI Vaccines (VBIV) , Novavax (NVAX) , Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD) .

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MGTX

MeiraGTx (MGTX) Stock Price, News & Analysis

$7.02

-0.10 (-1.40%)

(As of 12/29/2023 ET)

Compare

Today's Range: $6.92
▼
$7.32
50-Day Range: $3.60
▼
$7.15
52-Week Range: $3.49
▼
$8.77

Volume: 158,291 shs
Average Volume: 446,355 shs
Market Capitalization: $446.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.67

MeiraGTx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 265.6% Upside
$25.67 Price Target
Short Interest: Healthy
2.69% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.54
Upright™ Environmental Score
News Sentiment: 1.19
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.55) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

159th out of 950 stocks

Biological Products, Except Diagnostic Industry

22nd out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.67, MeiraGTx has a forecasted upside of 265.6% from its current price of $7.02.
Amount of Analyst Coverage
MeiraGTx has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.69% of the outstanding shares of MeiraGTx have been sold short.
Short Interest Ratio / Days to Cover
MeiraGTx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MeiraGTx has recently decreased by 0.58%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
MeiraGTx does not currently pay a dividend.
Dividend Growth
MeiraGTx does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MeiraGTx has received a 78.28% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for MeiraGTx is -0.54.

2.9

News and Social Media Coverage

News Sentiment
MeiraGTx has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MeiraGTx this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for MGTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MeiraGTx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of MeiraGTx is held by insiders.
Percentage Held by Institutions
64.84% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MeiraGTx are expected to grow in the coming year, from ($1.55) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MeiraGTx is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MeiraGTx is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MeiraGTx has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MeiraGTx Stock (NASDAQ:MGTX)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

MGTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MGTX Stock News Headlines

December 25, 2023 | finance.yahoo.com

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

December 24, 2023 | benzinga.com

MeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Report

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

December 23, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)

December 22, 2023 | benzinga.com

MeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Dates

December 21, 2023 | marketwatch.com

MeiraGTx Shares Rise 20% After Asset Purchase Deal With Janssen Pharma

December 21, 2023 | msn.com

MeiraGTx signs asset purchase agreement for bota-vec collaboration with Janssen

December 21, 2023 | msn.com

Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 21, 2023 | finance.yahoo.com

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

December 14, 2023 | finance.yahoo.com

The past three years for MeiraGTx Holdings (NASDAQ:MGTX) investors has not been profitable

November 15, 2023 | finance.yahoo.com

MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress

November 14, 2023 | benzinga.com

MeiraGTx Hldgs: Q3 Earnings Insights

November 14, 2023 | finance.yahoo.com

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

November 1, 2023 | markets.businessinsider.com

Buy Rating on Meiragtx Holdings: Promising Future with Sanofi Deal and Revolutionary Riboswitch Technology

October 31, 2023 | finance.yahoo.com

BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions

October 31, 2023 | msn.com

MeiraGTx (NASDAQ:MGTX) Surges After Sanofi’s $30 Million Investment

October 30, 2023 | proactiveinvestors.com

MeiraGTx shares take off on $30M investment by Sanofi

October 30, 2023 | za.investing.com

MeiraGTx's Sanofi deal shows 'significant underappreciated value' in portfolio and capabilities - Piper Sandler

October 25, 2023 | uk.finance.yahoo.com

MeiraGTx Holdings PLC (328.SG)

October 24, 2023 | finance.yahoo.com

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

September 19, 2023 | finance.yahoo.com

Individual investors own 27% of MeiraGTx Holdings plc (NASDAQ:MGTX) shares but private equity firms control 30% of the company

August 12, 2023 | msn.com

RBC Capital Maintains MeiraGTx Holdings (MGTX) Outperform Recommendation

August 12, 2023 | msn.com

Chardan Capital Reiterates MeiraGTx Holdings (MGTX) Buy Recommendation

August 11, 2023 | finance.yahoo.com

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2023 | finance.yahoo.com

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

August 1, 2023 | finance.yahoo.com

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

See More Headlines

Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MGTX
CUSIP: N/A
CIK: 1735438
Web: www.meiragtx.com
Phone: (646) 860-7985
Fax: N/A
Employees: 407
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.67
High Stock Price Target: $41.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +265.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-129,620,000.00
Net Margins: N/A
Pretax Margin: -1,966.74%
Return on Equity: -124.29%
Return on Assets: -44.45%

Debt

Debt-to-Equity Ratio: 0.94
Current Ratio: 1.63
Quick Ratio: 1.63

Sales & Book Value

Annual Sales: $15.92 million
Price / Sales: 28.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.43 per share
Price / Book: 2.89

Miscellaneous

Outstanding Shares: 63,600,000
Free Float: 57,428,000
Market Cap: $446.47 million
Optionable: Not Optionable
Beta: 1.45

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Alexandria Forbes Ph.D. (Age 58)
CEO, President & Director
Comp: $2.33M
Mr. Richard Brian Giroux B.A. (Age 50)
COO & CFO
Comp: $1.83M
Dr. Stuart Naylor Ph.D. (Age 60)
Chief Development Officer
Comp: $1M
Mr. Robert J. Wollin J.D. (Age 47)
General Counsel & Secretary
Dr. Michel Michaelides M.D.
Head of Clinical Ophthalmology
Ms. Christine Elise Sheehy (Age 56)
Senior Vice President of Global Integration
Mr. Tim Randall
Senior Vice President of Risk & Internal Controls
Dr. Alastair Leighton Ph.D.
Senior Vice President of Manufacturing & Supply Chain
Dr. Robert K. Zeldin M.D. (Age 60)
Chief Medical Officer
Comp: $1.1M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MeiraGTx stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGTX shares.
View MGTX analyst ratings or view top-rated stocks.
What is MeiraGTx's stock price target for 2024?: 2 analysts have issued 12 month price targets for MeiraGTx's shares. Their MGTX share price targets range from $11.00 to $41.00. On average, they expect the company's share price to reach $25.67 in the next year. This suggests a possible upside of 265.6% from the stock's current price.
View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts.
How have MGTX shares performed in 2023?: MeiraGTx's stock was trading at $6.52 at the beginning of the year. Since then, MGTX stock has increased by 7.7% and is now trading at $7.02.
View the best growth stocks for 2023 here.
When is MeiraGTx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our MGTX earnings forecast.

How were MeiraGTx's earnings last quarter?: MeiraGTx Holdings plc (NASDAQ:MGTX) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.11. The company had revenue of $5.10 million for the quarter, compared to the consensus estimate of $3.54 million.
What other stocks do shareholders of MeiraGTx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).
When did MeiraGTx IPO?: (MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.
How do I buy shares of MeiraGTx?: Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGTX) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial